Conference will be held October 29-31 at the Palace Hotel, San Francisco
NEW YORK, Oct. 24 /PRNewswire/ -- Gerson Lehrman Group, the world's
marketplace for expertise, and the Biotechnology Industry Organization
(BIO) have set the scientific agenda for the Seventh Annual BIO Investor
Forum. Featured therapeutic panels will include some of Gerson Lehrman
Group's leading physician consultants along with executives from public and
private equity biotechnology companies to discuss:
-- Congestive Heart Failure
-- Cystic Fibrosis
-- Lung Cancer
-- Neurodegenerative Diseases
-- Novel Solid Tumor Targets
-- Pre-ASH Primer
"With the financial markets experiencing an unprecedented level of volatility, investment professionals place a greater premium than ever before on sophisticated expertise to guide their decision-making," said Alexander Saint-Amand, President and Chief Executive Officer of Gerson Lehrman Group. "In the healthcare and biotechnology sectors, highly focused and unbiased education plays a critical role; the BIO Investor Forum brings together the three populations relevant to fully understand how to maneuver in this market: industry executives, sophisticated investors, and the world's top clinical thought leaders."
Through this partnership, BIO tapped Gerson Lehrman Group's network of more than 200,000 experts from around the world to identify clinicians and researchers to serve as panel speakers during the conference. The speakers were specifically identified to focus on some of the most interesting and novel development areas within the biotechnology industry, and represent some of the top clinical minds in their respective fields.
"This year's panel topics focus on disease areas in which we expect
innovative new therapies to produce significant clinical advances,
representing attractive investment and partnering
|SOURCE Gerson Lehrman Group|
Copyright©2008 PR Newswire.
All rights reserved